

Performance in Delivering - Q4: 2015/2016 (1st April 2015 - 31st March 2016) - non HRA studies

Research Ethics Committee Reference Number	IRAS number	Name of Trial	Target number of patients	Date Agreed to recruit target number of patients	Total number of patients recruited	Date Trial closed to recruitment	Reason for closure
12/SC/0025	88851	BRIGHTER (CRFB002E2402) A 24-month, phase IIIb, open-label, randomized, active-controlled, 3-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO)	6	29/05/2015	4	29/05/2015	Recruitment finished
13/EM/0254	131355	PROMETHEUS CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)	12	01/08/2015	3	01/08/2015	Recruitment finished
14/SC/0262	151493	CCRN 3322 SAFARI (AMD) A Phase IV, prospective, open-label, uncontrolled, European Study in patients with neovascular Age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching From intravitreal Aflibercept to Ranibizumab 0.5mg.	5	30/10/2016	1	17/11/2015	Withdrawn by Sponsor
13/EE/0241	133773	CCRN 2278 - SIGNATURE Secukinumab in patients with moderate to severe active, chronic plaque psoriasis who have failed on TNFa antagonists: A clinical trial evaluating treatment results (SIGNATURE Study CAIN457AGB01)	2	16/01/2015	3	17/04/2015	Recruitment finished
14/NW/0130	149373	RESPONSE (NT100) "A randomised, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)."	5	30/06/2015	8	08/12/2015	Recruitment finished
13/WM/0491	143648	Proteus Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy. (PROTEUS)	6	01/08/2015	4	01/08/2015	Recruitment finished
14/EM/0001	144027	TREND (CRFB002A2411) A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in patients with neovascular age-related macular degeneration	6	17/12/2015	3	17/12/2015	Recruitment finished
14/SC/0100	149880	JETREA FIRSTLINE (ALCON) - Assessment of Patients Treated With JETREA® for Vitreomacular Traction	6	30/09/2015	7	30/09/2015	Recruitment finished
13/LO/0733	127017	NCRN544 ADAPT AGS-003 + SOC in advanced RCC An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma	4	06/05/2015	0	06/05/2015	Recruitment finished

13/LO/1686	136550	ECLIPSE: Fovista™ and Lucentis® compared to Lucentis® alone in patients with AMD (Ophthotech) A Phase 3 randomised, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration.	5	30/11/2015	3	30/11/2015	Recruitment finished
14/EE/1001	156001	A 6 month, prospective, randomised, multicenter, placebo-controlled safety study of OTO-104 given at 3-month intervals by intratympanic injection in subjects with unilateral Meniere's disease followed by a 6-month open-label extension	4	17/04/2015	9	17/04/2015	Recruitment finished
13/NW/0462	130170	ACACIA: NCRN611 - Dose Finding Study of APD403 in CINV	15	30/01/2015	18	02/03/2015	Recruitment finished
14/YH/1090	158372	QUIET-1 - A Balanced Randomised Placebo Controlled Double-blind Phase IIa Study to Investigate the Efficacy and Safety of AUT00063 Versus Placebo in SubjectiveTinnitus	4	31/12/2015	1	08/10/2015	Withdrawn by Sponsor